Key result
THPO-ASO administration reduced blood platelet count and delayed the progression of metastatic breast cancer in transgenic MMTV-PyMT mice compared to untreated controls.
Why the study?
Platelets support pathological thrombosis and neoplastic proliferation, prompting investigators to test whether selectively silencing hepatic thrombopoietin could safely reduce platelet count and alter tumor progression.
Does THPO-ASO reduce platelet count and delay breast cancer progression in transgenic MMTV-PyMT mice?
Does THPO-ASO reduce platelet count and delay breast cancer progression in transgenic MMTV-PyMT mice?
Pharmacological reduction of platelet count using THPO-ASO is feasible and delays the progression of platelet-dependent pathological processes like breast cancer metastasis in a preclinical model.
This is the authors' abstract. We don't add key points for this paper.
In humans, platelet count within the normal range is required for physiological hemostasis, but, adversely, platelets also support pathological thrombosis. Moreover, by releasing growth factors, they may enhance neoplastic proliferation. We hypothesize that platelet count correlates with platelet-dependent pathologies, even within the range of hemostatic competence. Because platelet production is promoted by thrombopoietin signaling through the myeloproliferative leukemia virus oncogene (cMPL), a receptor expressed on megakaryocytes, we evaluated the feasibility of selective targeting of hepatic thrombopoietin production to test this hypothesis. We synthesized murine- and primate-specific antisense oligonucleotides (THPO-ASO) that silence hepatic thrombopoietin gene (THPO) expression without blocking extrahepatic THPO. Repeated doses of THPO-ASO were administered to mice and a baboon, causing a sustained 50% decline in plasma thrombopoietin levels and platelet count within 4 weeks in both species. To investigate whether reducing platelet count within the translationally relevant hemostatic range could alter a neoplastic process, we administered THPO-ASO to 6-week-old transgenic MMTV-PyMT mice that develop early ductal atypia that progresses into cMPL-negative fatal metastatic breast cancer within 2 to 3 months. THPO-ASO treatment increased the average time to euthanasia (primary humane endpoint) at 2 cm3 combined palpable tumor volume. Our results show that THPO-ASO reduced blood platelet count, plasma platelet factor 4, vascular endothelial growth factor, thrombopoietin levels, bone marrow megakaryocyte density, tumor growth rate, proliferation index, vascularization, platelet and macrophage content, and pulmonary metastases vs untreated controls. These findings confirm that sustained and moderate pharmacological platelet count reduction is feasible with THPO-ASO administration and can delay progression of certain platelet-dependent pathological processes within a safe hemostatic platelet count range.
Answers are grounded in this paper and cite their sources.
Platelet count in normal range may associate with thrombosis or cancer; leaves open whether cMPL modulation merits prospective trials.
No takes yet. Share an insight, caveat, or question.
Shirai et al. (2019) studied Breast cancer. THPO-ASO vs. untreated controls was evaluated on Average time to euthanasia at 2 cm3 combined palpable tumor volume. THPO-ASO administration reduced blood platelet count and delayed the progression of metastatic breast cancer in transgenic MMTV-PyMT mice compared to untreated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: